ibodutant
Small moleculeexperimental
Ibodutant was a candidate drug for irritable bowel syndrome diarrhea, developed by The Menarini Group. As of March 2015, it underwent a multicentre double blind efficacy clinical study. Ibodutant selectively blocks the tachykinin receptor NK2, with blockade practically complete in nanomolar concentrations. A phase 2 trial in Europe (the IRIS-2 trial) completed in May 2012 with positive results. A 52-week phase 3 study was terminated as of 2015 because of low response and negative results of study NAK-06. — Wikipedia
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT00761007)
Timeline
Indications
Studied for
Mechanism of action
- Neurokinin 2 receptorANTAGONIST
TACR2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc2cc(C(=O)NC3(C(=O)N[C@H](Cc4ccccc4)C(=O)NCC4CCN(CC5CCOCC5)CC4)CCCC3)sc2c1- Mol. weight
- 644.88 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaIbodutant ↗
- ChEMBLCHEMBL266125 ↗
Also known as
- 6-methylbenzo(b)thiophene-2-carboxylic acid (1-(2-phenyl-((1-(tetrahydropyran-4-ylmethyl)piperidin-4-ylmethyl)carbamoyl)ethylcarbamoyl)cyclophenyl)amide
- ibodutant
- ibodutant
- ibodutant
- ibodutant
- men15596
- men 15596
- men-15596
- men-15596
- men-15596
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02320318 | Phase 3 | Oct 1, 2015 | Katholieke Universiteit Leuven, Menarini Group |
| NCT02107196 | Phase 3 | Mar 1, 2014 | Katholieke Universiteit Leuven, Menarini Group, University of California, Los Angeles |
| NCT02120027 | Phase 3 | Feb 1, 2014 | Katholieke Universiteit Leuven, Menarini Group, University of California, Los Angeles |
| NCT01303224 | Phase 2 | Oct 1, 2010 | Katholieke Universiteit Leuven, Menarini Group |
| NCT00761007 | Phase 2 | Jul 1, 2008 | Katholieke Universiteit Leuven, Menarini Group |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Katholieke Universiteit Leuven | Academic/Hospital | 5 | 0 | 2 | 2008 |
| Menarini Group | For profit | 5 | 5 | 2 | 2008 |
| University of California, Los Angeles | Academic/Hospital | 2 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1